Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations

被引：3
作者：
Pelster, M. S. [1 ]
Yaeger, R. [2 ]
Klempner, S. J. [3 ]
Ou, S-H. I. [4 ]
Spira, A. I. [5 ,6 ]
Janne, P. A. [7 ]
Uboha, N. V. [8 ]
Gaffar, Y. A. [9 ]
Newman, G. [10 ]
Paweletz, C. P. [11 ]
Heavey, G. A. [12 ]
Alejandro, L. [13 ]
Kheoh, T. [14 ]
Anderes, K. [15 ]
Torossian, H. Der [16 ]
Christensen, J. G. [17 ]
Weiss, J. [18 ]
机构：
[1] Sarah Cannon Res Inst, Gastrointestinal Res, Nashville, TN USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] Massachusetts Gen Canc Ctr, Dept Med, Boston, MA USA
[4] UCI Hlth Chao Family Comprehens Canc Ctr, Dept Med, Orange, CA USA
[5] Virginia Canc Specialist, Res Inst, Fairfax, VA USA
[6] US Oncol Res, The Woodlands, TX USA
[7] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[8] Univ Wisconsin, Med, Madison, TX USA
[9] Maryland Oncol Hematol, Med Oncol, Columbia, MD 8 USA
[10] Ridley Tree Canc Ctr, Clin Res, Santa Barbara, CA USA
[11] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[12] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA USA
[13] Mirati Therapeut Inc, Med Affairs, San Diego, CA USA
[14] Mirati Therapeut Inc, Biometr, San Diego, CA USA
[15] Mirati Therapeut Inc, Translat Med & Compan Diagnost, San Diego, CA USA
[16] Mirati Therapeut Inc, Clin Dev, San Diego, CA USA
[17] Mirati Therapeut Inc, San Diego, CA USA
[18] Univ N Carolina, Lineberger Comprehens Canc Ctr, Oncol, Chapel Hill, NC USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
549O
引用
收藏
页码：S410 / S410
页数：1
相关论文
共 50 条
  • [21] Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
    Felip, E.
    Mok, T. S. K.
    Lu, S.
    Barlesi, F.
    Jotte, R.
    Lo Russo, G.
    Reck, M.
    Yao, W.
    Doucet, L.
    Martinez, A. Azkarate
    Gregorc, V.
    Juan-Vidal, O.
    Raskin, J.
    Linardou, H.
    Raina, R.
    Penton, H.
    Lee, A.
    Blum, S. I.
    Korytowsky, B.
    Duruisseaux, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S30 - S30
  • [22] Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib"
    Kosaka, Nanami
    Kataoka, Yuki
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (08) : e28 - e28
  • [23] Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12
    Barlesi, F.
    Yao, W.
    Duruisseaux, M.
    Doucet, L.
    Shi, J.
    Juan Vidal, O. J.
    Kim, Y-C.
    Garcia Campelo, M. R.
    Azkarate Martinez, A.
    Lu, S.
    Jotte, R.
    Felip, E.
    Lo Russo, G.
    Reck, M.
    Zhang, Y.
    Hu, N.
    Michenzie, M. F.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2024, 35 : 1247 - 1248
  • [24] Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series
    Bernstein, Ezra
    Luo, Jia
    Wang, Kaiwen
    Negrao, Marcelo V.
    Janne, Pasi A.
    Sabari, Joshua K.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [25] Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration
    Luo, Jia
    Villaruz, Liza C.
    LANCET RESPIRATORY MEDICINE, 2024, 12 (08) : 576 - 577
  • [26] Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases
    Negrao, Marcelo V.
    Spira, Alexander I.
    Heist, Rebecca S.
    Jaenne, Pasi A.
    Pacheco, Jose M.
    Weiss, Jared
    Gadgeel, Shirish M.
    Velastegui, Karen
    Yang, Wenjing
    Der-Torossian, Hirak
    Christensen, James G.
    Sabari, Joshua K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (28) : 4472 - +
  • [27] KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/ Metastatic KRASG12C-Mutated NSCLC
    Gadgeel, S.
    Janne, P. A.
    Spira, A. I.
    Ou, S. -H. I.
    Heist, R. S.
    Pacheco, J. M.
    Johnson, M. L.
    Sabari, J. K.
    Leventakos, K.
    Mason, J. A.
    Velastegui, K.
    Yan, X.
    Chao, R.
    Riely, G. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S118
  • [28] The combination of neratinib with sotorasib is synergistic in models of HER2-amplified and KRASG12C-mutated cancer
    Castel, Myra E.
    Conlon, Neil T.
    Walsh, Naomi
    Bischof, Georg F.
    Crown, John P.
    Collins, Denis M.
    CANCER RESEARCH, 2024, 84 (06)
  • [29] Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
    Salem, Mohamed E.
    El-Refai, Sherif M.
    Sha, Wei
    Puccini, Alberto
    Grothey, Axel
    George, Thomas J.
    Hwang, Jimmy J.
    O'Neil, Bert
    Barrett, Alexander S.
    Kadakia, Kunal C.
    Musselwhite, Laura W.
    Raghavan, Derek
    Van Cutsem, Eric
    Tabernero, Josep
    Tie, Jeanne
    JCO PRECISION ONCOLOGY, 2022, 6
  • [30] Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
    Shi, Yuankai
    Fang, Jian
    Xing, Ligang
    Yao, Yu
    Zhang, Jian
    Liu, Lian
    Wang, Yongsheng
    Hu, Changlu
    Xiong, Jianping
    Liu, Zhihua
    Yang, Runxiang
    Wang, Zhen
    Zhao, Enfeng
    Wang, Mengzhao
    Zhao, Yanqiu
    Tang, Kejing
    Li, Zhihua
    Song, Zhengbo
    Li, Yongsheng
    Zhuang, Wu
    Jin, Bo
    Cheng, Ying
    Hu, Yanping
    Gu, Yanhong
    Wu, Lin
    Ma, Rui
    Yu, Qitao
    Yu, Yan
    Zhao, Jun
    Zhao, Hui
    Lv, Dongqing
    Shang, Yanhong
    Xing, Puyuan
    Zhou, Jin
    Li, Xingya
    Liu, Zhe
    Dai, Zhaoxia
    Xia, Guohao
    Chen, Xueqin
    Ba, Yi
    Bai, Chunmei
    Li, Qingshan
    An, Guangyu
    Hu, Weiguo
    Wang, Yinxiang
    Wang-Gillam, Andrea
    Ding, Yuli
    Li, Qiao
    Rao, Zhiyue
    NATURE MEDICINE, 2025, : 894 - 900
12345